NCT01920932 · OUTCOME

Response Rate

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma · Source last updated 2026-05-06

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: after the first 2 cycles of chemotherapy (at approximately 2 months after enrollment)

What was measured

Response compared to the Euro-Net C1 after 2 cycles of AEPA.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Response compared to the Euro-Net C1 after 2 cycles of AEPA.
reporting Status: NOT_POSTED
time Frame: after the first 2 cycles of chemotherapy (at approximately 2 months after enrollment)
title: Response Rate
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice